Ryan Faucette

USPTO Granted Patents = 15 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 14)

Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 32(Granted Patents)

Company Filing History:

13 out of 1,177

Takeda Pharmaceutical Company Limited

Years Active: 2020-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12442824 - Assays for determining plasma kallikrein system biomarkers (2025-10-14),

2. 12384854 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema (2025-08-12),

3. 12188948 - Metabolite biomarkers for diseases associated with the contact activation system (2025-01-07),

4. 12135329 - Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK (2024-11-05),

5. 11884979 - RNA biomarkers for hereditary angioedema (2024-01-30),

6. 11826758 - Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation (2023-11-28),

7. 11815516 - Protein biomarkers for diseases associated with the contact activation system (2023-11-14),

8. 11668718 - Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK (2023-06-06),

9. 11458477 - Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation (2022-10-04),

10. 11372002 - Assays for determining plasma kallikrein system biomarkers (2022-06-28),

11. 11340237 - Metabolite biomarkers for diseases associated with the contact activation system (2022-05-24),

12. 11156612 - Methods of determining levels of cleaved and/or intact kininogen (2021-10-26),

13. 11084884 - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema (2021-08-10),

14. 10914747 - Immunoassay to detect cleaved high molecular weight kininogen (2021-02-09),

15. 10870115 - Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation (2020-12-22),

Title: The Innovative Contributions of Ryan Faucette

Introduction

Ryan Faucette is a notable inventor based in Melrose, MA (US), recognized for his significant contributions to the field of biomedical research. With a total of 15 patents to his name, Faucette has made strides in understanding and treating various medical conditions through innovative methodologies.

Latest Patents

Faucette's latest patents include groundbreaking work on assays for determining plasma kallikrein system biomarkers. These methods and assays are designed to assess the activation level of the plasma kallikrein (pKal) system and evaluate the effects of pKal modulators on this system. Another significant patent focuses on plasma kallikrein binding proteins, which are utilized in treating hereditary angioedema. This patent provides methods for using antibodies that bind to active plasma kallikrein, offering new avenues for treatment.

Career Highlights

Throughout his career, Faucette has worked with prominent companies in the pharmaceutical industry, including Takeda Pharmaceutical Company Limited and Dyax Corporation. His work in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical science.

Collaborations

Faucette has collaborated with esteemed colleagues such as Daniel J Sexton and Burt Adelman, further enhancing the impact of his research and inventions.

Conclusion

Ryan Faucette's contributions to the field of biomedical research through his patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of treatments for complex medical conditions.

This text is generated by artificial intelligence and may not be accurate.